U. Fainberg

Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of LIRA‐ADD2SGLT2i

L. Blonde, Ofri Mosenzon, Chethana Ramesh, 2021, Diabetes, obesity & metabolism.

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide

L. Rydén, S. Verma, J. Buse, 2021, Diabetes, obesity & metabolism.

Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial

L. Blonde, P. García-Hernández, R. Réa, 2020, Diabetes, obesity & metabolism.

Liraglutide in Children and Adolescents with Type 2 Diabetes.

W. Tamborlane, P. Hale, I. Libman, 2019, The New England journal of medicine.

Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.

N. Sattar, F. Visseren, S. Nuhoho, 2022, Diabetes care.